<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36219176</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>miRNA analysis reveals novel dysregulated pathways in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>934</StartPage><EndPage>947</EndPage><MedlinePgn>934-947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddac250</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Its complex pathogenesis and phenotypic heterogeneity hinder therapeutic development and early diagnosis. Altered RNA metabolism is a recurrent pathophysiologic theme, including distinct microRNA (miRNA) profiles in ALS tissues. We profiled miRNAs in accessible biosamples, including skin fibroblasts and whole blood and compared them in age- and sex-matched healthy controls versus ALS participants with and without repeat expansions to chromosome 9 open reading frame 72 (C9orf72; C9-ALS and nonC9-ALS), the most frequent ALS mutation. We identified unique and shared profiles of differential miRNA (DmiRNA) levels in each C9-ALS and nonC9-ALS tissues versus controls. Fibroblast DmiRNAs were validated by quantitative real-time PCR and their target mRNAs by 5-bromouridine and 5-bromouridine-chase sequencing. We also performed pathway analysis to infer biological meaning, revealing anticipated, tissue-specific pathways and pathways previously linked to ALS, as well as novel pathways that could inform future research directions. Overall, we report a comprehensive study of a miRNA profile dataset from C9-ALS and nonC9-ALS participants across two accessible biosamples, providing evidence of dysregulated miRNAs in ALS and possible targets of interest. Distinct miRNA patterns in accessible tissues may also be leveraged to distinguish ALS participants from healthy controls for earlier diagnosis. Future directions may look at potential correlations of miRNA profiles with clinical parameters.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hur</LastName><ForeName>Junguk</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of North Dakota, Grand Forks, ND 58202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paez-Colasante</LastName><ForeName>Ximena</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa-Romero</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Ting-Wen</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>Sami J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paulsen</LastName><ForeName>Michelle T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ljungman</LastName><ForeName>Mats</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alakwaa</LastName><ForeName>Fadhl M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savelieff</LastName><ForeName>Masha G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 TS000289</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 TS000327</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS127188</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS102960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>University of Michigan</Agency><Country/></Grant><Grant><GrantID>UL1TR002240</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS120926</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01TS000327</GrantID><Agency>ALS Association</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36219176</ArticleId><ArticleId IdType="pmc">PMC9990999</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddac250</ArticleId><ArticleId IdType="pii">6758292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman, S.A., Hardiman, O., Al-Chalabi, A., Chio, A., Savelieff, M.G., Kiernan, M.C. and Feldman, E.L. (2022) Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol., 21, 480&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman, S.A., Hardiman, O., Al-Chalabi, A., Chio, A., Savelieff, M.G., Kiernan, M.C. and Feldman, E.L. (2022) Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol., 21, 465&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon, G., Lacomblez, L. and Meininger, V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med., 330, 585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing, G. and Edaravone, A.L.S.S.G. (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol., 16, 505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji, R., Imai, T., Iwasaki, Y., Okamoto, K., Nakagawa, M., Ohashi, Y., Takase, T., Hanada, T., Shimizu, H., Tashiro, K. &#xa0;et al. (2019) Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J. Neurol. Neurosurg. Psychiatry, 90, 451&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6581107</ArticleId><ArticleId IdType="pubmed">30636701</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni, S., Macklin, E.A., Hendrix, S., Berry, J.D., Elliott, M.A., Maiser, S., Karam, C., Caress, J.B., Owegi, M.A., Quick, A. &#xa0;et al. (2020) Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N. Engl. J. Med., 383, 919&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara, Y. and Mieda-Sato, A. (2012) TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl. Acad. Sci. U. S. A., 109, 3347&#x2013;3352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295278</ArticleId><ArticleId IdType="pubmed">22323604</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Carlo, V., Grossi, E., Laneve, P., Morlando, M., Dini Modigliani, S., Ballarino, M., Bozzoni, I. and Caffarelli, E. (2013) TDP-43 regulates the microprocessor complex activity during in vitro neuronal differentiation. Mol. Neurobiol., 48, 952&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">24113842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagos-Quintana, M., Rauhut, R., Lendeckel, W. and Tuschl, T. (2001) Identification of novel genes coding for small expressed RNAs. Science, 294, 853&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau, N.C., Lim, L.P., Weinstein, E.G. and Bartel, D.P. (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science, 294, 858&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679671</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, R.C. and Ambros, V. (2001) An extensive class of small RNAs in Caenorhabditis elegans. Science, 294, 862&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679672</ArticleId></ArticleIdList></Reference><Reference><Citation>Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R. and Rajewsky, N. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature, 455, 58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">18668040</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak, J.S. and Michlewski, G. (2013) miRNAs in development and pathogenesis of the nervous system. Biochem. Soc. Trans., 41, 815&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863137</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Carroll, D. and Schaefer, A. (2013) General principals of miRNA biogenesis and regulation in the brain. Neuropsychopharmacology, 38, 39&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521995</ArticleId><ArticleId IdType="pubmed">22669168</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinchetti, P., Rizzuti, M., Faravelli, I. and Corti, S. (2018) MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis. Mol. Neurobiol., 55, 2617&#x2013;2630.</Citation><ArticleIdList><ArticleId IdType="pubmed">28421535</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitkanou, S., Della Gatta, P.A. and Russell, A.P. (2016) Skeletal muscle satellite cells, mitochondria, and micrornas: their involvement in the pathogenesis of ALS. Front. Physiol., 7, 403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5020084</ArticleId><ArticleId IdType="pubmed">27679581</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis, E., Aloizou, A.M., Siokas, V., Patrinos, G.P., Deretzi, G., Mitsias, P., Aschner, M. and Tsatsakis, A. (2018) The role of MicroRNAs in patients with amyotrophic lateral sclerosis. J. Mol. Neurosci., 66, 617&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">30415446</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero, C., Hur, J., Lunn, J.S., Paez-Colasante, X., Bender, D.E., Yung, R., Sakowski, S.A. and Feldman, E.L. (2016) Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol. Cell. Neurosci., 71, 34&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761498</ArticleId><ArticleId IdType="pubmed">26704906</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante, X., Figueroa-Romero, C., Sakowski, S.A., Goutman, S.A. and Feldman, E.L. (2015) Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat. Rev. Neurol., 11, 266&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H., Horbinski, C., Wu, H., Liu, Y., Sheng, S., Liu, J., Weiss, H., Stromberg, A.J. and Wang, C. (2016) NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data. Nucleic Acids Res., 44, e151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5175344</ArticleId><ArticleId IdType="pubmed">27471031</ArticleId></ArticleIdList></Reference><Reference><Citation>Tank, E.M., Figueroa-Romero, C., Hinder, L.M., Bedi, K., Archbold, H.C., Li, X., Weskamp, K., Safren, N., Paez-Colasante, X., Pacut, C. &#xa0;et al. (2018) Abnormal RNA stability in amyotrophic lateral sclerosis. Nat. Commun., 9, 2845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6054632</ArticleId><ArticleId IdType="pubmed">30030424</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen, M.T., Veloso, A., Prasad, J., Bedi, K., Ljungman, E.A., Tsan, Y.C., Chang, C.W., Tarrier, B., Washburn, J.G., Lyons, R. &#xa0;et al. (2013) Coordinated regulation of synthesis and stability of RNA during the acute TNF-induced proinflammatory response. Proc. Natl. Acad. Sci. U. S. A., 110, 2240&#x2013;2245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568384</ArticleId><ArticleId IdType="pubmed">23345452</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero, C., Hur, J., Bender, D.E., Delaney, C.E., Cataldo, M.D., Smith, A.L., Yung, R., Ruden, D.M., Callaghan, B.C. and Feldman, E.L. (2012) Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS One, 7, e52672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530456</ArticleId><ArticleId IdType="pubmed">23300739</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, A.H., Valdez, G., Moresi, V., Qi, X., McAnally, J., Elliott, J.L., Bassel-Duby, R., Sanes, J.R. and Olson, E.N. (2009) MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science, 326, 1549&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796560</ArticleId><ArticleId IdType="pubmed">20007902</ArticleId></ArticleIdList></Reference><Reference><Citation>Coenen-Stass, A.M.L., Wood, M.J.A. and Roberts, T.C. (2017) Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy. Trends Mol. Med., 23, 989&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">28988850</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, B., Liu, Z., Jiang, L., Liu, W., Song, M., Zhang, Q., Zhang, R., Cui, D., Wang, X. and Xu, S. (2017) Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Follow-up Study. J. Alzheimers Dis., 55, 509&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">27662297</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasso, M., Piscopo, P., Talarico, G., Ricci, L., Crestini, A., Tosto, G., Gasparini, M., Bruno, G., Denti, M.A. and Confaloni, A. (2019) Plasma microRNA profiling distinguishes patients with frontotemporal dementia from healthy subjects. Neurobiol. Aging, 84, 240 e241&#x2013;240 e212.</Citation><ArticleIdList><ArticleId IdType="pubmed">30826067</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell, A.P., Wada, S., Vergani, L., Hock, M.B., Lamon, S., L&#xe9;ger, B., Ushida, T., Cartoni, R., Wadley, G.D., Hespel, P. &#xa0;et al. (2013) Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol. Dis., 49, 107&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">22975021</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller, R., Goodall, E.F., Milo, M., Cooper-Knock, J., Da Costa, M., Hobson, E., Kazoka, M., Wollff, H., Heath, P.R., Shaw, P.J. &#xa0;et al. (2017) Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol. Aging, 55, 123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheja, R., Regev, K., Healy, B.C., Mazzola, M.A., Beynon, V., Von Glehn, F., Paul, A., Diaz-Cruz, C., Gholipour, T., Glanz, B.I. &#xa0;et al. (2018) Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve, 58, 261&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6103911</ArticleId><ArticleId IdType="pubmed">29466830</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt, A., Muller, K., Zondler, L., Weydt, P., Volk, A.E., Bozic, A.L., Walter, M., Bonin, M., Mayer, B., von &#xa0;Arnim, C.A. &#xa0;et al. (2014) Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain, 137, 2938&#x2013;2950.</Citation><ArticleIdList><ArticleId IdType="pubmed">25193138</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt, A., Muller, K., Zondler, L., Weydt, P., Mayer, B., von &#xa0;Arnim, C.A., Hubers, A., Dorst, J., Otto, M., Holzmann, K. &#xa0;et al. (2015) Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol. Aging, 36, 2660.e2615&#x2013;2660.e2620.</Citation><ArticleIdList><ArticleId IdType="pubmed">26142125</ArticleId></ArticleIdList></Reference><Reference><Citation>de &#xa0;Andrade, H.M., de &#xa0;Albuquerque, M., Avansini, S.H., de &#xa0;S Rocha, C., Dogini, D.B., Nucci, A., Carvalho, B., Lopes-Cendes, I. and Franca, M.C., Jr. (2016) MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J. Neurol. Sci., 368, 19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">27538595</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock, B.J., Bender, D.E., Segal, B.M. and Feldman, E.L. (2015) The dual roles of immunity in ALS: Injury overrides protection. Neurobiol. Dis., 77, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25726748</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock, B.J., Zhou, T., Kashlan, S.R., Little, R.J., Goutman, S.A. and Feldman, E.L. (2017) Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol., 74, 1446&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock, B.J., Bender, D.E., Kashlan, S.R., Figueroa-Romero, C., Backus, C., Callaghan, B.C., Goutman, S.A. and Feldman, E.L. (2016) Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm., 3, e242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897983</ArticleId><ArticleId IdType="pubmed">27308304</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock, B.J., Famie, J.P., Piecuch, C.E., Raue, K.D., Mendelson, F.E., Pieroni, C.H., Iniguez, S.D., Zhao, L., Goutman, S.A. and Feldman, E.L. (2021) NK cells associate with ALS in a sex- and age-dependent manner. JCI Insight, 6, e147129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262328</ArticleId><ArticleId IdType="pubmed">33974561</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock, B.J., Goutman, S.A., Boss, J., Kim, S. and Feldman, E.L. (2021) Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner. Neurol. Neuroimmunol. Neuroinflamm., 8, e953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057067</ArticleId><ArticleId IdType="pubmed">33531377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogribny, I.P. (2018) MicroRNAs as biomarkers for clinical studies. Exp. Biol. Med., 243, 283&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5813862</ArticleId><ArticleId IdType="pubmed">28914096</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori, M., Nuzziello, N., Introna, A., Consiglio, A., Licciulli, F., D'Errico, E., Scarafino, A., Distaso, E. and Simone, I.L. (2018) Dysregulation of MicroRNAs and target genes networks in peripheral blood of patients with sporadic amyotrophic lateral sclerosis. Front. Mol. Neurosci., 11, 288&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6121079</ArticleId><ArticleId IdType="pubmed">30210287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanda, A., Leonardis, L., Zidar, J., Koritnik, B., Dolenc-Groselj, L., Ristic Kovacic, S., Curk, T. and Rogelj, B. (2018) Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age-matched controls. Sci. Rep., 8, 5609&#x2013;5609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884852</ArticleId><ArticleId IdType="pubmed">29618798</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi, Y.H. and Wang, H. (2018) Exploring microRNA Biomarker for Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci., 19, 1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983737</ArticleId><ArticleId IdType="pubmed">29710810</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi, H. and Tomari, Y. (2016) RISC assembly: Coordination between small RNAs and Argonaute proteins. Biochim. Biophys. Acta, 1859, 71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">26303205</ArticleId></ArticleIdList></Reference><Reference><Citation>Houseley, J. and Tollervey, D. (2009) The many pathways of RNA degradation. Cell, 136, 763&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">19239894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y., Choe, J., Park, O.H. and Kim, Y.K. (2020) Molecular Mechanisms Driving mRNA Degradation by m(6)A Modification. Trends Genet., 36, 177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">31964509</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero, C., Monteagudo, A., Murdock, B.J., Famie, J.P., Webber-Davis, I.F., Piecuch, C.E., Teener, S.J., Pacut, C., Goutman, S.A. and Feldman, E.L. (2022) Tofacitinib suppresses natural killer cells in vitro and in vivo: implications for amyotrophic lateral sclerosis. Front. Immunol., 13, 773288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8859451</ArticleId><ArticleId IdType="pubmed">35197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra, R., Hanker, A.B. and Garrett, J.T. (2017) Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget, 8, 114371&#x2013;114392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5768410</ArticleId><ArticleId IdType="pubmed">29371993</ArticleId></ArticleIdList></Reference><Reference><Citation>Modol-Caballero, G., Garcia-Lareu, B., Verdes, S., Ariza, L., Sanchez-Brualla, I., Brocard, F., Bosch, A., Navarro, X. and Herrando-Grabulosa, M. (2020) Therapeutic Role of Neuregulin 1 Type III in SOD1-Linked Amyotrophic Lateral Sclerosis. Neurotherapeutics, 17, 1048&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609630</ArticleId><ArticleId IdType="pubmed">31965551</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi, Y., Fukuda, Y., Yoshimura, J., Toyoda, A., Kurppa, K., Moritoyo, H., Belzil, V.V., Dion, P.A., Higasa, K., Doi, K. &#xa0;et al. (2013) ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am. J. Hum. Genet., 93, 900&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824132</ArticleId><ArticleId IdType="pubmed">24119685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahana, T.G. and Zhang, K. (2021) Mitogen-Activated Protein Kinase Pathway in Amyotrophic Lateral Sclerosis. Biomedicine, 9, 969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394856</ArticleId><ArticleId IdType="pubmed">34440173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs, K.L., Kalmar, B., Rhymes, E.R., Fellows, A.D., Ahmed, M., Whiting, P., Davies, C.H., Greensmith, L. and Schiavo, G. (2018) Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis., 9, 596&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964181</ArticleId><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui, Y., Zhao, Z., Liu, R., Cai, B. and Fan, D. (2014) Adenosine monophosphate-activated protein kinase activation enhances embryonic neural stem cell apoptosis in a mouse model of amyotrophic lateral sclerosis. Neural Regen. Res., 9, 1770&#x2013;1778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238165</ArticleId><ArticleId IdType="pubmed">25422638</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman, S.A., Guo, K., Savelieff, M.G., Patterson, A., Sakowski, S.A., Habra, H., Karnovsky, A., Hur, J. and Feldman, E.L. (2022) Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain. 10.1093/brain/awac025. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac025</ArticleId><ArticleId IdType="pmc">PMC9762943</ArticleId><ArticleId IdType="pubmed">35088843</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman, S.A., Boss, J., Guo, K., Alakwaa, F.M., Patterson, A., Kim, S., Savelieff, M.G., Hur, J. and Feldman, E.L. (2020) Untargeted metabolomics yields insight into ALS disease mechanisms. J. Neurol. Neurosurg. Psychiatry, 91, 1329&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677469</ArticleId><ArticleId IdType="pubmed">32928939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel, P., Donkervoort, S., Lone, M.A., Nalls, M., Gable, K., Gupta, S.D., Foley, A.R., Hu, Y., Saute, J.A.M., Moreira, A.L. &#xa0;et al. (2021) Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat. Med., 27, 1197&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309980</ArticleId><ArticleId IdType="pubmed">34059824</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, J.O., Chia, R., Miller, D.E., Li, R., Kumaran, R., Abramzon, Y., Alahmady, N., Renton, A.E., Topp, S.D., Gibbs, J.R. &#xa0;et al. (2021) Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurol., 78, 1236&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406220</ArticleId><ArticleId IdType="pubmed">34459874</ArticleId></ArticleIdList></Reference><Reference><Citation>Vall&#xe9;e, A., Lecarpentier, Y., Guillevin, R. and Vall&#xe9;e, J.-N. (2018) Thermodynamics in neurodegenerative diseases: interplay between canonical WNT/Beta-catenin pathway-PPAR gamma, energy metabolism and circadian rhythms. NeuroMolecular Med., 20, 174&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">29572723</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S.-P. and Wang, L.-H. (2016) Disease implication of hyper-Hippo signalling. Open Biol., 6, 160119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5090056</ArticleId><ArticleId IdType="pubmed">27805903</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukic, S., McMackin, R., Buxo, T., Fasano, A., Chipika, R., Pinto-Grau, M., Costello, E., Schuster, C., Hammond, M., Heverin, M. &#xa0;et al. (2019) Patterned functional network disruption in amyotrophic lateral sclerosis. Hum. Brain Mapp., 40, 4827&#x2013;4842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6852475</ArticleId><ArticleId IdType="pubmed">31348605</ArticleId></ArticleIdList></Reference><Reference><Citation>Recabarren-Leiva, D. and Alarc&#xf3;n, M. (2018) New insights into the gene expression associated to amyotrophic lateral sclerosis. Life Sci., 193, 110&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">29241710</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, T., Baldie, G., Periz, G. and Wang, J. (2014) RNA-processing protein TDP-43 regulates FOXO-dependent protein quality control in stress response. PLoS Genet., 10, e1004693&#x2013;e1004693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199500</ArticleId><ArticleId IdType="pubmed">25329970</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia, R., Chio, A. and Traynor, B.J. (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol., 17, 94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, C.H., Fallini, C., Ticozzi, N., Keagle, P.J., Sapp, P.C., Piotrowska, K., Lowe, P., Koppers, M., McKenna-Yasek, D., Baron, D.M. &#xa0;et al. (2012) Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature, 488, 499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzeri, C., De Palma, C., Martinuzzi, A., Daga, A., De Polo, G., Bresolin, N., Miller, C.C., Tudor, E.L., Clementi, E. and Bassi, M.T. (2006) The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function. Brain, 129, 1710&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pubmed">16670179</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner, J.M., Al-Chalabi, A., Baker, M.R., Cui, L.Y., de &#xa0;Carvalho, M., Eisen, A., Grosskreutz, J., Hardiman, O., Henderson, R., Matamala, J.M. &#xa0;et al. (2020) A proposal for new diagnostic criteria for ALS. Clin. Neurophysiol., 131, 1975&#x2013;1978.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, B.R., Miller, R.G., Swash, M. and Munsat, T.L. (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 1, 293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>He, F., Jones, J.M., Figueroa-Romero, C., Zhang, D., Feldman, E.L., Goutman, S.A., Meisler, M.H., Callaghan, B.C. and Todd, P.K. (2016) Screening for novel hexanucleotide repeat expansions at ALS- and FTD-associated loci. Neurol. Genet., 2, e71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865132</ArticleId><ArticleId IdType="pubmed">27274540</ArticleId></ArticleIdList></Reference><Reference><Citation>Valeri, N., Braconi, C., Gasparini, P., Murgia, C., Lampis, A., Paulus-Hock, V., Hart, J.R., Ueno, L., Grivennikov, S.I., Lovat, F. &#xa0;et al. (2014) MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell, 25, 469&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995091</ArticleId><ArticleId IdType="pubmed">24735923</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachos, I.S., Zagganas, K., Paraskevopoulou, M.D., Georgakilas, G., Karagkouni, D., Vergoulis, T., Dalamagas, T. and Hatzigeorgiou, A.G. (2015) DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res., 43, W460&#x2013;W466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489228</ArticleId><ArticleId IdType="pubmed">25977294</ArticleId></ArticleIdList></Reference><Reference><Citation>McGregor, B.A., Eid, S., Rumora, A.E., Murdock, B., Guo, K., de &#xa0;Anda-Jauregui, G., Porter, J.E., Feldman, E.L. and Hur, J. (2018) Conserved transcriptional signatures in human and murine diabetic peripheral neuropathy. Sci. Rep., 8, 17678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6281650</ArticleId><ArticleId IdType="pubmed">30518872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader, G.D. and Hogue, C.W. (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 4, 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149346</ArticleId><ArticleId IdType="pubmed">12525261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn, M. (2008) Building predictive models in R using the caret package. J. Stat. Softw., 28, 1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C. and M&#xfc;ller, M. (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics, 12, 77&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>